A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury
Study Overview This study aimed to evaluate the efficacy and safety of MLC901 (NeuroAiDTMII) as a treatment for cognitive impairment […]
